| Rx0000077 |
AbbVie |
03/31/2020 |
00074634702 |
HUMIRA (adalimumab) 10mg/0.2mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074937402 |
HUMIRA (adalimumab) 20mg/0.4mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379906 |
HUMIRA (adalimumab) 40MG/0.8ML , 6 Syringe |
01/01/2020 |
1148.65 |
16670.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433902 |
HUMIRA (adalimumab) 40mg/0.8mL, 2 Pen |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379902 |
HUMIRA (adalimumab) 40mg/0.8mL, 2 Syringe |
01/01/2020 |
382.88 |
5556.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074379903 |
HUMIRA (adalimumab) 40MG/0.8ML, 3 Syringe |
01/01/2020 |
574.32 |
8335.48 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433907 |
HUMIRA (adalimumab) 40mg/0.8mL, 4 Pen |
01/01/2020 |
765.76 |
11113.96 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074433906 |
HUMIRA (adalimumab) 40mg/0.8mL, 6 Pen |
01/01/2020 |
1148.65 |
16670.97 |
06/03/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074105305 |
LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 11.25mg, 1 Kit |
01/01/2020 |
288.69 |
4189.84 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074105205 |
LUPANETA (leuprolide acetate for depot suspension and norethindrone acetate) 3.75mg, 1 Kit |
01/01/2020 |
96.23 |
1396.60 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074366303 |
LUPRON DEPOT (leuprolide acetate) 11.25mg, 1 Kit |
01/01/2020 |
288.69 |
4189.84 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074334603 |
LUPRON DEPOT (leuprolide acetate) 22.5mg, 1 Kit |
01/01/2020 |
344.01 |
4992.79 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074364103 |
LUPRON DEPOT (leuprolide acetate) 3.75mg, 1 Kit |
01/01/2020 |
96.23 |
1396.60 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074368303 |
LUPRON DEPOT (leuprolide acetate) 30mg, 1 Kit |
01/01/2020 |
458.68 |
6657.06 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074347303 |
LUPRON DEPOT (leuprolide acetate) 45mg, 1 Kit |
01/01/2020 |
688.03 |
9985.73 |
02/05/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074364203 |
LUPRON DEPOT (leuprolide acetate) 7.5mg, 1 Kit |
01/01/2020 |
114.67 |
1664.27 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074377903 |
LUPRON DEPOT PED (leuprolide acetate) 11.25mg, 1 Kit (3 mo) |
01/01/2020 |
630.49 |
9150.69 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074228203 |
LUPRON DEPOT PED (leuprolide acetate) 11.25mg, PDS Kit |
01/01/2020 |
210.16 |
3050.22 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074244003 |
LUPRON DEPOT PED (leuprolide acetate) 15mg, 1 Kit |
01/01/2020 |
231.47 |
3359.51 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074969403 |
LUPRON DEPOT PED (leuprolide acetate) 30mg, 1 Kit |
01/01/2020 |
694.43 |
10078.56 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074210803 |
LUPRON DEPOT PED (leuprolide acetate) 7.5mg, 1 Kit |
01/01/2020 |
115.76 |
1680.11 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057611 |
VENCLEXTA (venetoclax) 100mg, 1 Tablet |
01/01/2020 |
4.88 |
102.44 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057622 |
VENCLEXTA (venetoclax) 100mg, 120 Tablet |
01/01/2020 |
585.40 |
12293.47 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056114 |
VENCLEXTA (venetoclax) 10mg, 14 2 TABLETS X 7 |
01/01/2020 |
6.83 |
143.42 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056111 |
VENCLEXTA (venetoclax) 10mg, 2 Tablet |
01/01/2020 |
0.98 |
20.49 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074057928 |
VENCLEXTA (venetoclax) 10MG, 50MG, 100MG , 1 4X7 DAY WALLET |
01/01/2020 |
126.35 |
2653.34 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056611 |
VENCLEXTA (venetoclax) 50mg, 1 Tablet |
01/01/2020 |
2.44 |
51.22 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000077 |
AbbVie |
03/31/2020 |
00074056607 |
VENCLEXTA (venetoclax) 50mg, 7 1 TABLET X 7 |
01/01/2020 |
17.07 |
358.56 |
09/06/2033 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
06/30/2020 |
63090034030 |
NUPLAZID Oral Capsule 34 MG 30 |
06/29/2020 |
297.00 |
3638.00 |
08/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
06/30/2020 |
63090010030 |
NUPLAZID Oral Tablet 10 MG 30 |
06/29/2020 |
297.00 |
3638.00 |
08/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
03/31/2020 |
42192071401 |
Ciclopirox Treatment External Kit,8%, 34.6 ML, Cream |
01/03/2020 |
46.03 |
316.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=455, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=457 |
Columns 14 through 22 were left blank because this product was not acquired from another manufacturer within the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
09/30/2020 |
42192071401 |
Ciclopirox Treatment External Kit, 8%, 34.6 ML, Cream |
08/03/2020 |
14.22 |
330.22 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=456 |
Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192011270 |
Salicylic Acid External Foam, 6 %, Size 70GM, Unit-of-Use, Can, |
10/05/2020 |
6.97 |
161.76 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=458 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192014301 |
Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 100GM, Unit-of-Use, Can |
10/05/2020 |
16.90 |
392.54 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=459 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
12/31/2020 |
42192014360 |
Sulfacetamide Sodium-Sulfur (SSS) 10-5 External Foam 10-5 %, Size 60GM, Unit-of-Use, Can |
10/05/2020 |
12.68 |
294.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=460 |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000201 |
BELEODAQ (belinostat) Injection 500 mg |
04/01/2020 |
30.01 |
2031.00 |
10/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1885.30 |
None |
2014 |
1500.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
72893000201 |
BELEODAQ (belinostat) Injection 500 mg, Single dose vial |
01/01/2020 |
29.57 |
2000.99 |
10/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1885.30 |
None |
2014 |
1500.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=416 |
Acrotech Biopharma is updating the NDC number for Beleodaq to replace Spectrum Pharmaceutical’s labeler code (68152) with Acrotech Biopharma’s (72893) labeler code.
Please see the below:
• New NDC (Acrotech): 72893-0002-01
• Old NDC (Spectrum): 68152-0109-00 |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
48818000101 |
FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial |
01/01/2020 |
57.14 |
5770.87 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
5442.69 |
None |
2009 |
3125.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
48818000101 |
FOLOTYN (pralatrexate) Injection 20 mg, 20mg/mL, 1mL vial |
04/01/2020 |
109.65 |
5880.52 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
5442.69 |
None |
2009 |
3125.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
48818000102 |
FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial |
01/01/2020 |
114.27 |
11541.74 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
10885.38 |
None |
2009 |
6250.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
48818000102 |
FOLOTYN (pralatrexate) Injection 40 mg,20mg/mL, 2mL vial |
04/01/2020 |
219.29 |
11761.04 |
05/31/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
10885.38 |
None |
2009 |
6250.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
68152011201 |
KHAPZORY (levoleucovorin) injection 175, Single dose vial mg |
01/01/2020 |
7.00 |
707.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
700.00 |
None |
2019 |
700.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
03/31/2020 |
68152011401 |
KHAPZORY (levoleucovorin) injection 300 mg, Single dose vial |
01/01/2020 |
12.00 |
1212.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Sprectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
1200.00 |
None |
2019 |
1200.00 |
None |
None |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000803 |
MARQIBO (vincristine sulfate) Injection 5 mg, 5mg/31mL, Single-Dose Vial |
04/01/2020 |
587.90 |
15662.36 |
09/25/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
14294.21 |
None |
2013 |
9750.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=440 |
There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 20, 2020 |
| Rx0000157 |
Acrotech Biopharma LLC |
06/30/2020 |
72893000704 |
ZEVALIN (Ibritumomab Tiuxetan), Injection 3.2 mg, 3.2mg/2mL, Single-Dose 2mL Vial |
04/01/2020 |
821.32 |
55575.64 |
12/31/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Spectrum Pharmaceuticals |
16000000 |
None |
Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. |
49949.21 |
None |
2002 |
40068.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=441 |
There was an NDC change to move from the Sprectrum Pharmaceuticals NDC to Acrotech Biopharma's NDC. Please see attached Notification dated May 19, 2020 |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431011001 |
JUXTAPID 10 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431012001 |
JUXTAPID 20 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431013001 |
JUXTAPID 30 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431014001 |
JUXTAPID 40 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431010501 |
JUXTAPID 5 MG CAPS - bottle of 28 |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431016001 |
JUXTAPID 60 MG CAPS, bottle of 28 capsules |
01/01/2020 |
4042.68 |
44713.53 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was developed by the manufacturer therefore the acquisition related fields are blank. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2020 |
76431021001 |
MYALEPT 11.3MG VIAL |
01/01/2020 |
460.50 |
5093.32 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/12/2015 |
Astra Zeneca |
325000000 |
None |
None |
3493.00 |
3493.00 |
2014 |
3493.00 |
None |
The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as shown in MediSpan. |
| Rx0000085 |
Akorn Inc |
03/31/2020 |
17478050305 |
Dehydrated Alcohol 0.98mL/mL, 5mL, 10 |
01/24/2020 |
3172.57 |
4467.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14:22- Acquisition information not applicable as this is an Akorn developed product. Column 6- No known patents. This NDC is an unapproved product and does not have an FDA approved application. |
| Rx0000085 |
Akorn Inc |
09/30/2020 |
17478071130 |
Lidocaine Hydrochloride Jelly 2%, 30mL |
08/17/2020 |
30.56 |
106.96 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14:22- Acquisition information not applicable as this is an Akorn developed product. |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040403 |
ARISTADA 1064 mg/3.9mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
187.42 |
3311.21 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040103 |
ARISTADA 441 mg/ 1.6mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
77.68 |
1372.41 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040203 |
ARISTADA 662 mg/2.4mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
116.61 |
2060.17 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000039 |
Alkermes, Inc |
06/30/2020 |
65757040303 |
ARISTADA 882 mg/3.2mL extended-release injectable suspension, 1 pre-filled syringe |
04/03/2020 |
155.36 |
2744.82 |
03/19/2035 |
Single Source Drug |
None |
1 |
This information is not in the public domain or not otherwise publicly available, but Alkermes believes that every patient deserves quality care and access to the treatments they need. We strive to price our medicines in a responsible manner that facilitates broad access. To this end, we work collaboratively with the government, private payers, and health systems to design and implement equitable access and patient support services for the vulnerable patient populations we serve. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Aristada was developed in-house |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932110 |
ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.99 |
335.77 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932115 |
ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.99 |
503.73 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023932105 |
ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.00 |
167.96 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917710 |
ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.05 |
358.04 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917715 |
ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
25.58 |
537.11 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023917705 |
ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.53 |
179.07 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456046101 |
ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.68 |
161.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045701 |
ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
3.21 |
67.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045801 |
ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
3.77 |
79.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456045901 |
ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
4.19 |
87.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456046001 |
ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
6.56 |
137.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980002210 |
BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980002205 |
BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456141030 |
BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456141090 |
BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140263 |
BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.33 |
510.86 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140230 |
BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456142030 |
BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456142090 |
BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140563 |
BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.33 |
510.86 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140530 |
BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.16 |
150.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456140590 |
BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.49 |
451.20 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
58914017014 |
CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE |
01/03/2020 |
10.46 |
219.74 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
58914017110 |
CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.43 |
407.94 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921110 |
COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.63 |
370.31 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921115 |
COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
26.45 |
555.43 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023921105 |
COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.82 |
185.15 |
01/19/2023 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456221230 |
FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456220228 |
FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
18.33 |
384.95 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456222030 |
FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456224030 |
FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456228030 |
FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.64 |
412.44 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980022810 |
FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.28 |
320.81 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980022805 |
FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.64 |
160.40 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980021110 |
FML-0.1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
15.28 |
320.81 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980021105 |
FML-0.1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.64 |
160.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456201001 |
LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
57.37 |
1204.72 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456202001 |
LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
59.86 |
1257.13 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456200501 |
LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
54.87 |
1152.25 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120130 |
LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120230 |
LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120330 |
LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.19 |
445.02 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00430042014 |
LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
35.15 |
738.75 |
02/02/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320503 |
LUMIGAN-0.01 %-2.5-DROPS |
01/03/2020 |
9.85 |
206.82 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320505 |
LUMIGAN-0.01 %-5-DROPS |
01/03/2020 |
19.69 |
413.47 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023320508 |
LUMIGAN-0.01 %-7.5-DROPS |
01/03/2020 |
29.53 |
620.17 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456430001 |
MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE |
01/03/2020 |
4.35 |
91.27 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456121430 |
NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122130 |
NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122830 |
NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456122929 |
NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.59 |
453.40 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456120730 |
NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
23.13 |
485.79 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018010 |
PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018015 |
PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE |
01/03/2020 |
21.82 |
458.29 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980018005 |
PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980017410 |
PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE |
01/03/2020 |
14.55 |
305.53 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
11980017405 |
PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023006604 |
PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM) |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023010605 |
PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) |
01/03/2020 |
7.27 |
152.76 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023530105 |
RESTASIS MULTIDOSE-0.05 %-5.5-DROPS |
01/03/2020 |
27.89 |
585.61 |
05/11/2034 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023916330 |
RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.94 |
292.79 |
08/27/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023916360 |
RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
27.89 |
585.61 |
08/27/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456151060 |
SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456150055 |
SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE |
01/03/2020 |
17.51 |
367.61 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456151260 |
SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456152560 |
SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456155060 |
SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
19.10 |
401.03 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023586228 |
TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 1 |
01/03/2020 |
9.35 |
196.30 |
03/29/2020 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023586230 |
TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE PACK OF 5 |
01/03/2020 |
46.74 |
981.48 |
03/29/2020 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456040001 |
TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 |
01/03/2020 |
9.61 |
201.73 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456040010 |
TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 |
01/03/2020 |
96.06 |
2017.27 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456060001 |
TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 1 |
01/03/2020 |
9.61 |
201.73 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456060010 |
TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE PACK OF 10 |
01/03/2020 |
96.06 |
2017.27 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
61874010060 |
VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
62.73 |
1317.39 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
61874007560 |
VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE |
01/03/2020 |
62.73 |
1317.39 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456110130 |
VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456111030 |
VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456112030 |
VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00456114030 |
VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE |
01/03/2020 |
13.61 |
285.85 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611001 |
ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
16.75 |
351.77 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030602 |
ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
16.75 |
351.77 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611101 |
ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
24.19 |
508.06 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611201 |
ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
32.86 |
690.13 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030302 |
ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
32.86 |
690.13 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611601 |
ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
40.67 |
854.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030502 |
ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
40.67 |
854.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611301 |
ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.88 |
186.51 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030402 |
ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.88 |
186.51 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611401 |
ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
64.86 |
1362.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030702 |
ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
64.86 |
1362.01 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
00023611501 |
ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.47 |
177.95 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2020 |
42865030002 |
ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE |
01/03/2020 |
8.47 |
177.95 |
02/20/2028 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110050201 |
Acticlate 150mg 60 tablet |
01/02/2020 |
102.33 |
2204.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110050101 |
Acticlate 75mg 60 tablet |
01/02/2020 |
102.33 |
2204.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023367060 |
Aczone 5% 60 g |
01/02/2020 |
52.24 |
687.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
593.63 |
542.13 |
2008 |
343.48 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023367090 |
Aczone 5% 90g |
01/02/2020 |
68.52 |
901.68 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
778.65 |
711.10 |
2008 |
516.21 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023520660 |
Aczone 7.5% 60g |
01/02/2020 |
52.24 |
687.42 |
11/18/2033 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
Indication extended to 9 years; post marketing commitment completed |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
593.63 |
542.13 |
2016 |
495.10 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023520690 |
Aczone 7.5% 90g |
01/02/2020 |
68.52 |
901.68 |
11/18/2033 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
Indication extended to 9 years; post marketing commitment completed |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
778.65 |
711.10 |
2016 |
649.41 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110051815 |
Altabax 1% ointment 15g |
01/02/2020 |
14.73 |
315.03 |
02/14/2027 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
151.64 |
128.83 |
2007 |
217.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110051830 |
Altabax 1% ointment 30g |
01/02/2020 |
28.79 |
604.67 |
02/14/2027 |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
288.82 |
245.38 |
2007 |
415.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023869450 |
Azelex 50g |
01/02/2020 |
32.52 |
682.92 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
607.85 |
555.11 |
1995 |
308.69 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110002660 |
Cordan 0.05% Ointment 60g |
01/02/2020 |
37.64 |
738.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110003512 |
Cordran 0.05% Cream 120g |
01/02/2020 |
62.37 |
1224.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110005212 |
Cordran 0.05% Lotion 120ml |
01/02/2020 |
62.37 |
1224.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023587080 |
Cordran Tape 4 ug/cm2, 1500cm2 |
01/02/2020 |
34.02 |
714.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
635.87 |
580.70 |
2016 |
580.70 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110081230 |
Fluoroplex 1% cream 30g |
01/02/2020 |
45.90 |
900.92 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915530 |
Tazorac Cream .05% 30g |
01/02/2020 |
19.93 |
418.46 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
372.46 |
340.15 |
2000 |
221.55 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915560 |
Tazorac Cream .05% 60g |
01/02/2020 |
39.85 |
836.76 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
744.78 |
680.16 |
2000 |
443.01 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915630 |
Tazorac Cream 0.1% 30g |
01/02/2020 |
21.17 |
444.56 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
395.69 |
361.36 |
2000 |
235.36 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023915660 |
Tazorac Cream 0.1% 60g |
01/02/2020 |
42.33 |
888.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
791.26 |
722.61 |
2000 |
784.49 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023004210 |
Tazorac Gel .01% 100g |
01/02/2020 |
70.56 |
1481.75 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
1318.87 |
1204.45 |
1997 |
784.49 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023004203 |
Tazorac Gel .01% 30g |
01/02/2020 |
21.17 |
444.56 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
395.69 |
361.36 |
1997 |
235.36 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023833510 |
Tazorac Gel .05% 100g |
01/02/2020 |
66.41 |
1394.53 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
1241.23 |
1133.54 |
1997 |
738.30 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
00023833503 |
Tazorac Gel .05% 30g |
01/02/2020 |
19.93 |
418.46 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
09/21/2018 |
Allergan |
None |
None |
Allergan products were acquired as a portfolio for a total price of $550 million. The company does not have a specific methodology to allocate the portfolio price among the aquired products. |
372.46 |
340.15 |
1997 |
217.00 |
None |
The company does not have access to launch WACs prior to 2013 for acquired products |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110007130 |
Veltin 1.2%/0.025% gel 30g |
01/02/2020 |
22.04 |
462.74 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
243.07 |
220.97 |
2010 |
148.00 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110007160 |
Veltin 1.2%/0.025% gel 60g |
01/02/2020 |
41.49 |
871.24 |
None |
Single Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
11/15/2015 |
GlaxoSmithKline |
None |
1 |
None |
456.61 |
415.10 |
2010 |
278.00 |
None |
Year of introduction from CMS Medicaid rebate database |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110011100 |
Verdeso 0.05% foam 100g |
01/02/2020 |
50.57 |
992.41 |
08/13/2027 |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2020 |
16110008045 |
Xolegel 2% gel 45g |
01/02/2020 |
40.06 |
786.28 |
None |
Innovator Multiple Source Drug |
None |
1 |
When pricing its products, Almirall takes into consideration multiple factors, including but not limited to: research and development (or asset acquisition) investments, including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts, fees, and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends, including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
59338077510 |
ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg/17 mL CTN/10 |
01/01/2020 |
412.10 |
10714.20 |
06/30/2023 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
12/31/2020 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme 510mg Each |
10/01/2020 |
42.86 |
1114.28 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
12/31/2020 |
59338077510 |
ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 |
10/01/2020 |
428.60 |
11142.80 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme (Ferumoxytol Injection) 510mg Each |
01/01/2020 |
41.21 |
1071.42 |
06/30/2023 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2020 |
64011060128 |
Intrarosa (prasterone) 6.5mg vaginal insert Package of 28 |
01/01/2020 |
10.30 |
212.30 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
02/14/2017 |
US commercial rights licensed from Endoceutics |
50000000 |
None |
At closing, AMAG will pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. In addition, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of Intrarosa and $10 million upon the first anniversary of the effective date of the agreement. Endoceutics will be entitled to certain sales milestone payments, including a first sales milestone payment of $15 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150 million, and a second milestone payment of $30 million, which would be triggered when annual net U.S. sales exceed $300 million. Should annual net U.S. sales exceed $500 million, there are additional sales milestone payments of up to $850 million, which would be triggered at various sales thresholds. AMAG will also pay Endoceutics tiered royalties as a percent of Intrarosa net sales. |
1.00 |
0.00 |
2017 |
175.00 |
None |
Product acquired pre-launch |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2020 |
52937000120 |
Vascepa(Icosapent ethyl) 120 1g |
12/29/2020 |
13.24 |
344.22 |
06/28/2033 |
Single Source Drug |
3158613 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2020 |
52937000340 |
Vascepa(Icosapent ethyl) 240 500mg |
12/29/2020 |
15.49 |
402.73 |
06/28/2033 |
Single Source Drug |
3485 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
60687012125 |
ACAMPROSATE CALCIUM DR TABLET 333MG 30UD |
11/02/2020 |
17.32 |
58.97 |
None |
Non-innovator Multiple Source Drug |
8953 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
09/30/2020 |
60687031425 |
Azithromycin Tablet 600mg 30UD |
09/22/2020 |
45.79 |
159.27 |
None |
Non-innovator Multiple Source Drug |
1818 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039700 |
FAMOTIDINE TAB 20MG 100 |
12/01/2020 |
7.23 |
14.00 |
None |
Non-innovator Multiple Source Drug |
107510 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039708 |
FAMOTIDINE TAB 20MG 1000 |
12/01/2020 |
78.28 |
140.00 |
None |
Non-innovator Multiple Source Drug |
20150 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039800 |
FAMOTIDINE TAB 40MG 100 |
12/01/2020 |
15.77 |
28.00 |
None |
Non-innovator Multiple Source Drug |
48412 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2020 |
68001039803 |
FAMOTIDINE TAB 40MG 500 |
12/01/2020 |
40.02 |
140.00 |
None |
Non-innovator Multiple Source Drug |
7288 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
03/31/2020 |
68084082321 |
Methylphenidate HCl Tablet CII 10mg 30UD |
01/16/2020 |
10.23 |
44.41 |
None |
Non-innovator Multiple Source Drug |
5487 |
None |
Market conditions |
None |
No change/improvement in drug product description/Not applicable. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
09/30/2020 |
68084067601 |
Metoclopramide Tablet 10mg 100UD |
07/24/2020 |
20.00 |
60.00 |
None |
Non-innovator Multiple Source Drug |
19755 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
06/30/2020 |
60687037401 |
NABUMETONE TAB 500MG 100UD |
04/06/2020 |
13.19 |
118.19 |
None |
Non-innovator Multiple Source Drug |
1278 |
None |
Market Conditions |
None |
No change or improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
03/31/2020 |
60687015625 |
Phenytoin Chew Tablet 50mg 30UD |
02/26/2020 |
15.59 |
45.00 |
None |
Non-innovator Multiple Source Drug |
10773 |
None |
Market conditions |
None |
No change/improvement in the drug product description |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000128 |
American Regent |
09/30/2020 |
00517065001 |
Injectafer Intravenous Solution 750 MG/15ML |
07/01/2020 |
33.19 |
1139.67 |
02/15/2028 |
Single Source Drug |
696537 |
None |
American Regent’s US Standards of Business Conduct (available at https://www.americanregent.com/media/2747/us-sobc-112019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Injectafer is not an acquired product. American Regent is the NDA holder of this NDC. |
| Rx0000128 |
American Regent |
03/31/2020 |
00517037405 |
PROVAYBLUE (METHYLENE BLUE) 5 MG/ML, 10 ML AMPULE, PKG. OF 5 |
03/31/2020 |
156.82 |
1189.87 |
None |
Innovator Multiple Source Drug |
67316967 |
None |
American Regent’s US Standards of Business Conduct (available at http://ari.americanregent.com/Files/Compliance/US_Standards_of_Business_Conduct_21NOV2019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
No improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ProvayBlue is not an acquired product. The partner from whom we license the drug, (which is not affiliated with American Regent) is the NDA holder of this NDC. |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066930 |
Emverm Chewable Tablet 100 MG |
02/25/2020 |
41.92 |
465.31 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
405.53 |
None |
2018 |
405.53 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
60846030115 |
Nizatidine Oral Solution 15mg/mL 480 Bottle |
01/20/2020 |
50.63 |
557.41 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Gemini |
None |
1 |
None |
419.59 |
None |
2018 |
419.59 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069701 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 100 tablets |
07/06/2020 |
44.18 |
486.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
381.56 |
381.56 |
2019 |
381.56 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069713 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 60 tablets |
07/06/2020 |
26.51 |
291.85 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
228.94 |
228.94 |
2019 |
228.94 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069801 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 100 tablets |
07/06/2020 |
61.26 |
674.52 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
529.13 |
529.13 |
2019 |
529.13 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069813 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 60 tablets |
07/06/2020 |
36.76 |
404.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
317.48 |
317.48 |
2019 |
317.48 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069901 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 100 tablets |
07/06/2020 |
78.36 |
862.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
676.74 |
676.74 |
2019 |
676.74 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069913 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 60 tablets |
07/06/2020 |
47.01 |
517.62 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
406.05 |
406.05 |
2019 |
406.05 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070001 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 100 tablets |
07/06/2020 |
112.78 |
1241.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
974.06 |
974.06 |
2019 |
974.06 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070013 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 60 tablets |
07/06/2020 |
67.67 |
745.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
584.44 |
584.44 |
2019 |
584.44 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070101 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 100 tablets |
07/06/2020 |
147.21 |
1620.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
1271.39 |
1271.39 |
2019 |
1271.39 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896070113 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 60 tablets |
07/06/2020 |
88.32 |
972.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
762.84 |
762.84 |
2019 |
762.84 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069501 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 100 tablets |
07/06/2020 |
23.01 |
253.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
198.71 |
198.71 |
2019 |
198.71 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069513 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 60 tablets |
07/06/2020 |
13.80 |
151.98 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
119.22 |
119.22 |
2019 |
119.22 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069601 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 100 tablets |
07/06/2020 |
33.59 |
369.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
290.12 |
290.12 |
2019 |
290.12 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
09/30/2020 |
64896069613 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 60 tablets |
07/06/2020 |
20.15 |
221.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
174.07 |
174.07 |
2019 |
174.07 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066101 |
Rytary 23.75mg/95mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066201 |
Rytary 36.25mg/145mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066301 |
Rytary 48.75mg/195mg ER Cap 100ct |
02/25/2020 |
14.42 |
334.98 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
291.68 |
None |
2018 |
291.68 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896066401 |
Rytary 61.25mg/245mg ER Cap 100ct |
02/25/2020 |
18.13 |
420.92 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
366.51 |
None |
2018 |
366.51 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896067151 |
Zomig 2.5 mg 6 tab blister |
02/25/2020 |
69.92 |
776.18 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
584.75 |
None |
2018 |
584.75 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896068251 |
Zomig 2.5 mg Nasal Spray (2x3 packs) |
02/25/2020 |
48.08 |
533.73 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
402.09 |
None |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896067250 |
Zomig 5 mg 3 tab blister |
02/25/2020 |
34.96 |
388.08 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
292.37 |
None |
2018 |
292.37 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896068151 |
Zomig 5 mg Nasal Spray (2x3 packs) |
02/25/2020 |
48.08 |
533.73 |
None |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
402.09 |
None |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
12/31/2020 |
64896068251 |
Zomig Nasal Solution 2.5 MG, Package size of 6 tablets |
12/01/2020 |
52.84 |
586.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
402.09 |
402.09 |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
12/31/2020 |
64896068151 |
Zomig Nasal Solution 5 MG, Package size of 6 tablets |
12/01/2020 |
52.84 |
586.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
402.09 |
402.09 |
2018 |
402.09 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896069151 |
Zomig ZMT 2.5 mg 6 tab blister |
02/25/2020 |
69.92 |
776.18 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
584.75 |
None |
2018 |
584.75 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2020 |
64896069250 |
Zomig ZMT 5 mg 3 tab blister |
02/25/2020 |
34.96 |
388.08 |
None |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/10/1905 |
Impax |
None |
1 |
None |
292.37 |
None |
2018 |
292.37 |
None |
None |
| Rx0000176 |
ANIP |
03/31/2020 |
62559067030 |
Arimidex 1mg Tab 30 |
03/01/2020 |
129.93 |
1497.59 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559068030 |
Casodex 50mg Tab 30 |
03/01/2020 |
285.97 |
3296.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559011107 |
Cortenema 100mg/60mL Enema 7 |
03/01/2020 |
33.82 |
166.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559013807 |
HC 100mg/60mL Enema 7 |
03/01/2020 |
30.55 |
150.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052201 |
Inderal LA 120mg Cap 100 |
03/01/2020 |
646.29 |
7449.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052301 |
Inderal LA 160mg Cap 100 |
03/01/2020 |
674.68 |
7776.58 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052001 |
Inderal LA 60mg Cap 100 |
03/01/2020 |
502.45 |
5791.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559052101 |
Inderal LA 80mg Cap 100 |
03/01/2020 |
586.87 |
6764.41 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559060130 |
Inderal XL 120mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559060030 |
Inderal XL 80mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559059130 |
InnoPran XL 120mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559059030 |
InnoPran XL 80mg Cap 30 |
03/01/2020 |
173.84 |
2003.74 |
10/04/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559028001 |
Lithobid 300mg Tab 100 |
03/01/2020 |
110.57 |
1274.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559016601 |
Reglan 10mg Tab 100 |
03/01/2020 |
29.54 |
340.48 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559016501 |
Reglan 5mg Tab 100 |
03/01/2020 |
29.54 |
340.48 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559031020 |
Vancocin 125mg Cap 20 |
03/01/2020 |
149.44 |
1722.44 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000176 |
ANIP |
03/31/2020 |
62559031120 |
Vancocin 250mg Cap 20 |
03/01/2020 |
275.52 |
3175.78 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
ANI pharmaceuticals puts careful consideration into determining the value and the cost of our medicines. |
| Rx0000274 |
Artesa Labs, LLC |
06/30/2020 |
57893020360 |
Nicaprin, Dietary Supplement, Tablet, 60 ct. |
05/30/2020 |
54.00 |
590.00 |
None |
Single Source Drug |
17838 |
None |
Raw materials, regulations |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2020 |
13913001201 |
Cambia (diclofenac potassium) 50MG Oral 1 Packet |
01/03/2020 |
7.49 |
83.11 |
06/16/2026 |
Single Source Drug |
959886 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2020 |
13913000812 |
Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle |
01/03/2020 |
141.48 |
1570.55 |
02/24/2029 |
Single Source Drug |
2806920 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077660 |
Brilinta 60mg Tablets 60 count bottle |
07/01/2020 |
7.71 |
393.03 |
01/27/2036 |
Single Source Drug |
181368340 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077739 |
Brilinta 90mg Tablets 100 count box |
07/01/2020 |
12.85 |
655.04 |
01/27/2036 |
Single Source Drug |
28772299 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186077760 |
Brilinta 90mg Tablets 60 count bottle |
07/01/2020 |
7.71 |
393.03 |
01/27/2036 |
Single Source Drug |
1182543013 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310654004 |
Bydureon 2mg Autoinjector 4 Syringes |
07/01/2020 |
14.42 |
735.18 |
10/04/2030 |
Single Source Drug |
668761831 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
407.45 |
None |
2012 |
323.44 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310653004 |
Bydureon 2mg Pen 4 Syringes |
07/01/2020 |
14.42 |
735.18 |
03/21/2028 |
Single Source Drug |
815082319 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
407.45 |
None |
2012 |
323.44 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310009530 |
Daliresp 500mcg Tablets 30 count bottle |
07/01/2020 |
21.67 |
382.85 |
03/08/2024 |
Single Source Drug |
214201592 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/04/2015 |
Forest Laboratories, LLC |
280000000 |
None |
The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. |
257.88 |
None |
2011 |
172.50 |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310009590 |
Daliresp 500mcg Tablets 90 count bottle |
07/01/2020 |
65.01 |
1148.57 |
03/08/2024 |
Single Source Drug |
49787415 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/04/2015 |
Forest Laboratories, LLC |
280000000 |
None |
The Daliresp acquisition was part of a larger acquisition that included other assets, the estimated portion for Daliresp was approximately $280 million. The acquisition was made from Forest Laboratories, LLC which was owned by Actavis PLC at the time of acquisition. |
773.65 |
None |
2012 |
517.50 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310621030 |
Farxiga 10mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
05/26/2030 |
Single Source Drug |
1438170485 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
289.20 |
2014 |
289.20 |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310621030 |
Farxiga 10mg tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
05/26/2030 |
Single Source Drug |
1438170485 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
None |
2014 |
289.20 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310620530 |
Farxiga 5mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
05/26/2030 |
Single Source Drug |
590696676 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
289.20 |
2014 |
289.20 |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310620530 |
Farxiga 5mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
05/26/2030 |
Single Source Drug |
590696676 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
02/01/2014 |
Bristol-Myers Squibb |
2700000000 |
None |
AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. |
289.20 |
None |
2014 |
289.20 |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310678030 |
Qtern 5mg-10mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
12/16/2029 |
Single Source Drug |
10919684 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310678030 |
Qtern 5mg-10mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
12/16/2029 |
Single Source Drug |
10919684 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037020 |
Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler |
07/01/2020 |
7.15 |
364.38 |
10/07/2029 |
Innovator Multiple Source Drug |
None |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037028 |
Symbicort 160/4.5mcg HFA Aerosol 1 Inhaler Inst Pack |
07/01/2020 |
4.85 |
247.60 |
10/07/2029 |
Innovator Multiple Source Drug |
159106270 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037220 |
Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler |
07/01/2020 |
6.25 |
318.78 |
10/07/2029 |
Innovator Multiple Source Drug |
1020316295 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00186037228 |
Symbicort 80/4.5mcg HFA Aerosol 1 Inhaler Inst Pack |
07/01/2020 |
4.22 |
215.24 |
10/07/2029 |
Innovator Multiple Source Drug |
43272143 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310628030 |
Xigduo XR 10-1000mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
128234044 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310628030 |
Xigduo XR 10-1000mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
128234044 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310627030 |
Xigduo XR 10-500mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
13548819 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310627030 |
Xigduo XR 10-500mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
13548819 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310626060 |
Xigduo XR 5-1000mg Tablets 60 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
237728896 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310626060 |
Xigduo XR 5-1000mg Tablets 60 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
237728896 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000015 |
AstraZeneca |
03/31/2020 |
00310625030 |
Xigduo XR 5-500mg Tablets 30 Count Bottle |
01/01/2020 |
14.77 |
507.18 |
11/12/2030 |
Single Source Drug |
23387060 |
None |
"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. " |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report. |
| Rx0000015 |
AstraZeneca |
09/30/2020 |
00310625030 |
Xigduo XR 5-500mg Tablets 30 count bottle |
07/01/2020 |
10.14 |
517.32 |
11/12/2030 |
Single Source Drug |
23387060 |
None |
AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions:
- We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them.
- We seek feedback from payers and providers through meetings, advisory boards, and third party research.
- We price responsibly and in line with current treatment costs where treatment options exist.
- We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs.
- We reinvest into R&D to identify future medicines to improve the lives of patients. |
None |
AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000265 |
Atland Pharmaceuticals |
06/30/2020 |
71993030030 |
Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets (325 mg/ 30 mg/ 16 mg) |
04/02/2020 |
150.00 |
600.00 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Atland acquired product ANDA 204209 from Larken the rights to market and distribute the NDC under a licensing agreement, the terms of which are not publicly available. |
| Rx0000058 |
Avanir Pharmaceuiticals |
03/31/2020 |
64597030160 |
NUEDEXTA (Dextromethorphan hydrobromide 20mg and quinidine sulfate 10mg capsules); 60 capsules per bottle |
01/01/2020 |
76.40 |
1250.40 |
08/13/2026 |
Single Source Drug |
None |
1 |
Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The reason for the blank acquisition-related fields (14-22) is that Neudexta was not acquired. |